HIGHLIGHTS
- who: Yasuyuki Matsumoto from the Department have published the Article: Targeting Tn-positive tumors with an afucosylated recombinant anti-Tn IgG, in the Journal: Scientific Reports Scientific Reports
- what: The authors demonstrate that an afucosylated chimeric, human anti-Tn IgG1 mAb (Remab6-AF) has potent ADCC activity in_vitro and anti-tumor efficacy in_vivo.
- how: To evaluate the therapeutic potential of a chimeric anti-Tn mAb that binds to human carcinomas the authors analyzed the cytotoxic activity in_vitro. As little is known about CDC activity of an afucosylated mAb to cancer cells the authors . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.